Herantis Pharma Oyj
HEL:HRTIS.HE
1.69 (EUR) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.025 | 0.002 | 0.001 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0.928 | 0 | 1.202 | 1.218 | 0.027 | 11.268 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | -0.928 | -1.047 | -1.202 | -1.218 | -0.002 | -11.266 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.071 | -5,762.797 | 0 | 0 | 1 | 0 |
| Reseach & Development Expenses
| 3.6 | 2.7 | 5 | 6.2 | 5.328 | 4.928 | 2.1 | 2.328 | 2.728 | 4.9 | 3.8 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2.988 | 0.002 | 2.649 | 2.85 | 2.834 | 2.334 | 1.244 | 1.024 | 0.942 | 1.332 | 1.734 | 0.454 | 0.383 | 1.432 |
| Other Expenses
| 1.562 | -2.856 | 0 | 1.295 | 0.709 | 0.824 | 0.23 | 0.593 | 0.749 | 16.168 | 2.124 | 0.515 | 0 | 0 |
| Operating Expenses
| 5.026 | -0.154 | 7.993 | 9.05 | 8.072 | 7.155 | 3.668 | 1.024 | 4.418 | 16.168 | 7.657 | 0.752 | 0.383 | 1.437 |
| Operating Income
| -5.026 | 0.154 | -7.993 | -9.05 | -8.072 | -7.155 | -4.871 | -2.242 | -4.42 | -16.166 | -7.657 | -0.752 | -0.38 | -1.474 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -174.773 | -8,269.183 | -9,570.802 | 0 | -8,647.528 | 0 |
| Total Other Income Expenses Net
| 0.087 | 0.125 | -1.331 | -0.306 | -1.081 | -0.849 | 0.691 | 0.077 | -0.004 | 0.122 | -0.7 | -0.028 | -0.014 | 0.028 |
| Income Before Tax
| -4.939 | 0.28 | -9.324 | -12.767 | -9.153 | -8.005 | -4.18 | -2.165 | -4.425 | -16.045 | -8.356 | -0.781 | -0.394 | -1.446 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -174.944 | -8,206.999 | -10,445.554 | 0 | -8,962.443 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Net Income
| -4.939 | 0.28 | -9.324 | -23.576 | -9.153 | -8.005 | -4.18 | -2.165 | -4.425 | -16.045 | -8.356 | -0.781 | -0.394 | -1.446 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -174.944 | -8,206.999 | -10,445.554 | 0 | -8,962.489 | 0 |
| EPS
| -0.24 | 0.016 | -0.64 | -2.197 | -1.18 | -1.3 | -0.85 | -0.51 | -1.02 | -3.75 | -3.05 | -0.67 | -71.16 | -261.53 |
| EPS Diluted
| -0.24 | 0.016 | -0.64 | -2.197 | -1.18 | -1.3 | -0.85 | -0.51 | -1.02 | -3.747 | -3.05 | -0.67 | -0.32 | -1.19 |
| EBITDA
| -4.934 | 0.831 | 7.979 | 6.921 | -7.144 | -6.089 | -2.917 | -0.638 | -3.139 | -6.539 | -6.345 | -0.45 | -0.339 | -1.395 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -124.118 | -3,344.915 | -7,931.021 | 0 | -7,710.57 | 0 |